<?xml version="1.0"?>
<?xml-stylesheet type="text/css" href="http://www.vokipedia.de/skins/common/feed.css?303"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="de">
		<id>http://www.vokipedia.de/index.php?action=history&amp;feed=atom&amp;title=Natural_History_Studies%3A_Danon_Disease</id>
		<title>Natural History Studies: Danon Disease - Versionsgeschichte</title>
		<link rel="self" type="application/atom+xml" href="http://www.vokipedia.de/index.php?action=history&amp;feed=atom&amp;title=Natural_History_Studies%3A_Danon_Disease"/>
		<link rel="alternate" type="text/html" href="http://www.vokipedia.de/index.php?title=Natural_History_Studies:_Danon_Disease&amp;action=history"/>
		<updated>2026-05-06T03:23:57Z</updated>
		<subtitle>Versionsgeschichte dieser Seite in Vokipedia</subtitle>
		<generator>MediaWiki 1.19.23</generator>

	<entry>
		<id>http://www.vokipedia.de/index.php?title=Natural_History_Studies:_Danon_Disease&amp;diff=254050&amp;oldid=prev</id>
		<title>OlgaHay61616 am 1. Dezember 2025 um 19:19 Uhr</title>
		<link rel="alternate" type="text/html" href="http://www.vokipedia.de/index.php?title=Natural_History_Studies:_Danon_Disease&amp;diff=254050&amp;oldid=prev"/>
				<updated>2025-12-01T19:19:33Z</updated>
		
		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table class='diff diff-contentalign-left'&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
			&lt;tr valign='top'&gt;
			&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;← Nächstältere Version&lt;/td&gt;
			&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Version vom 1. Dezember 2025, 19:19 Uhr&lt;/td&gt;
			&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Zeile 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Zeile 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;br&amp;gt;RP-A501 is being developed for Danon Disease, a rare genetic disorder characterized by thickening and weakening of the heart muscle, often resulting in heart failure, &lt;del class=&quot;diffchange diffchange-inline&quot;&gt; [https://gitea.sosaley.in/madeleinedanne/9185alpha-surge-male-supplement/wiki/25-Best-Resistance-Band-Exercises-%26-Q0-Resistance-Band-Workouts-for-every-Muscle-Group Alpha Surge Male strength formula] &lt;/del&gt;and for male patients, frequent death during adolescence or early adulthood. Rocket is the first company demonstrating safety and &lt;del class=&quot;diffchange diffchange-inline&quot;&gt; [https://lab.chocomart.kz/gwxleanne50671/2475alpha-surge-male-reviews/issues/11 Alpha Surge Male strength formula] &lt;/del&gt;efficacy data in clinical studies for gene therapy targeting the heart. An open-label, global Phase 2 pivotal clinical trial of RP-A501 for the treatment of Danon Disease has commenced. The trial is expected to enroll 12 &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;[https://git.ngcr.de/elinorstleon15 alpha surge &lt;/del&gt;male &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;official site] &lt;/del&gt;patients from the U.S. EU. The trial will assess a co-primary endpoint consisting of LAMP2 protein expression and left ventricular (LV) mass reduction from baseline at 12 months. Natural History studies are observational studies that gather comprehensive data on the course of the disease to gain a better understanding of its progression and impact on patients. Data captured may include information on the physical signs and symptoms patients experience, test results (for example blood tests or imaging), genetic information, and health-related quality of life, over a period of time.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;This information helps describe the disease course and identify important factors (e.g. demographic, genetic, and/or lab test results), that may contribute to better or worse disease outcomes. Travel, accommodation, and food stipend would be provided. Study assessments are provided free of charge. Natural History Studies are particularly important for rare diseases. Given the diversity of symptoms and the small size of the patient population, these studies are often the only opportunity for researchers and physicians to address significant knowledge gaps and obtain a robust understanding of the disease and patient experience. Understanding characteristics of the patient population to define a treatment benefit from a patient’s perspective. Provide patient-centric data for health authorities such as the FDA, and other public health institutions to use in their review processes of investigational treatments. Interested in learning more? To read our Expanded Access statement, click here. RP-A501 is being developed for Danon Disease, a rare genetic disorder characterized by thickening and &lt;del class=&quot;diffchange diffchange-inline&quot;&gt; [https://45.76.249.136/index.php?title=User:KlausBehrens Alpha Surge Male strength formula] &lt;/del&gt;weakening of the heart muscle, often resulting in heart failure, and for &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;[http://www.gitea.zhangc.top:3000/floragalarza8 Alpha Surge Male strength formula] &lt;/del&gt;patients, frequent death during adolescence or early adulthood.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Rocket is the first company demonstrating safety and efficacy data in clinical studies for gene therapy targeting the heart. An open-label, global Phase 2 pivotal clinical trial of RP-A501 for the treatment of Danon Disease has commenced. The trial is expected to enroll 12 male patients from the U.S. EU. The trial will assess a co-primary endpoint consisting of LAMP2 protein expression and left ventricular (LV) mass reduction from baseline at 12 months. Rocket is sponsoring a multi-center, global, non-interventional natural history study designed to collect longitudinal prospective and retrospective clinical information on &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;[https://gitea.siriusun.com/chandrakaiser alpha surge &lt;/del&gt;male&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;] &lt;/del&gt;and female patients with Danon Disease. The overarching goal of the study is to characterize the natural history of Danon Disease by collecting de-identified information from patients living with the condition. &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;Initial trial sites for the natural history study in the U.S. EU have been identified and are currently enrolling patients. If you are diagnosed with Danon Disease or a family member and are interested in potentially enrolling in the Danon Disease Natural History Study,&amp;#160; [http://git.konsulterna.nu:3000/zanetyler78000 alpha surge male official site] [http://git.gkcorp.com.vn:16000/frankiegoodlet alpha surge male supplement] male muscle builder please contact us.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Natural History studies are observational studies that gather comprehensive data on the course of the disease to gain a better understanding of its progression and impact on patients. Data captured may include information on the physical signs and symptoms patients experience, test results (for example blood tests or imaging), genetic information, and&amp;#160; [https://wiki.snooze-hotelsoftware.de/index.php?title=Benutzer:Damaris5665 Alpha Surge Male strength formula] health-related quality of life, over a period of time. This information helps describe the disease course and identify important factors (e.g. demographic, genetic, and/or lab test results),&amp;#160; [https://wiki.heycolleagues.com/index.php/User:RafaelKopf75558 Alpha Surge Male strength formula] that may contribute to better or worse disease outcomes. Travel, accommodation, and food stipend would be provided. Study assessments are provided free of charge. Natural History Studies are particularly important for rare diseases. Given the diversity of symptoms and the small size of the patient population, these studies are often the only opportunity for researchers and physicians to address significant knowledge gaps and obtain a robust understanding of the disease and patient experience. Understanding characteristics of the patient population to define a treatment benefit from a patient’s perspective. Provide patient-centric data for health authorities such as the FDA, and other public health institutions to use in their review processes of investigational treatments. Interested in learning more? To read our Expanded Access statement, click here. 2025 Rocket Pharmaceuticals. © Rocket Pharmaceuticals, Ltd.&amp;lt;br&amp;gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;br&amp;gt;RP-A501 is being developed for Danon Disease, a rare genetic disorder characterized by thickening and weakening of the heart muscle, often resulting in heart failure, and for male patients, frequent death during adolescence or early adulthood. Rocket is the first company demonstrating safety and efficacy data in clinical studies for gene therapy targeting the heart. An open-label, global Phase 2 pivotal clinical trial of RP-A501 for the treatment of Danon Disease has commenced. The trial is expected to enroll 12 male patients from the U.S. EU. The trial will assess a co-primary endpoint consisting of LAMP2 protein expression and left ventricular (LV) mass reduction from baseline at 12 months. Natural History studies are observational studies that gather comprehensive data on the course of the disease to gain a better understanding of its progression and impact on patients. Data captured may include information on the physical signs and symptoms patients experience, test results (for example blood tests or imaging), genetic information, and &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt; [https://corona-untersuchungsausschuss.org/index.php?title=You_Should_Eat_The_Entire_Egg_To_Build_Muscle Titan Rise Capsules] &lt;/ins&gt;health-related quality of life, over a period of time.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;This information helps describe the disease course and identify important factors (e.g. demographic, genetic, and/or lab test results), that may contribute to better or worse disease outcomes. Travel, accommodation, and &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt; [https://git.pwcedge-sbs-innov-lab.com/orlandoi82494/2646655/wiki/The+Top+8+Mass-Building+Machines.- Titan Rise Capsules] &lt;/ins&gt;food stipend would be provided. Study assessments are provided free of charge. Natural History Studies are particularly important for rare diseases. Given the diversity of symptoms and &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt; [https://trade-britanica.trade/wiki/Titan_Rise:_The_Ultimate_Supplement_For_Male_Performance_And_Health Titan Rise Capsules] &lt;/ins&gt;the small size of the patient population, these studies are often the only opportunity for researchers and physicians to address significant knowledge gaps and obtain a robust understanding of the disease and patient experience. Understanding characteristics of the patient population to define a treatment benefit from a patient’s perspective. Provide patient-centric data for health authorities such as the FDA, and other public health institutions to use in their review processes of investigational treatments. Interested in learning more? To read our Expanded Access statement, click here. RP-A501 is being developed for Danon Disease, a rare genetic disorder characterized by thickening and weakening of the heart muscle, often resulting in heart failure, and for &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;male &lt;/ins&gt;patients, frequent death during adolescence or &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt; Titan Rise Male Enhancement &lt;/ins&gt;early adulthood.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Rocket is the first company demonstrating safety and efficacy data in clinical studies for gene therapy targeting the heart. An open-label, global Phase 2 pivotal clinical trial of RP-A501 for the treatment of Danon Disease has commenced. The trial is expected to enroll 12 male patients from the U.S. EU. The trial will assess a co-primary endpoint consisting of LAMP2 protein expression and left ventricular (LV) mass reduction from baseline at 12 months. Rocket is sponsoring a multi-center, global, non-interventional natural history study designed to collect longitudinal prospective and retrospective clinical information on male and female patients with Danon Disease. The overarching goal of the study is to characterize the natural history of Danon Disease by collecting de-identified information from patients living with the condition.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>OlgaHay61616</name></author>	</entry>

	<entry>
		<id>http://www.vokipedia.de/index.php?title=Natural_History_Studies:_Danon_Disease&amp;diff=178416&amp;oldid=prev</id>
		<title>JosetteHandley am 12. Oktober 2025 um 01:21 Uhr</title>
		<link rel="alternate" type="text/html" href="http://www.vokipedia.de/index.php?title=Natural_History_Studies:_Danon_Disease&amp;diff=178416&amp;oldid=prev"/>
				<updated>2025-10-12T01:21:55Z</updated>
		
		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table class='diff diff-contentalign-left'&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
				&lt;col class='diff-marker' /&gt;
				&lt;col class='diff-content' /&gt;
			&lt;tr valign='top'&gt;
			&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;← Nächstältere Version&lt;/td&gt;
			&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Version vom 12. Oktober 2025, 01:21 Uhr&lt;/td&gt;
			&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Zeile 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Zeile 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;−&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;br&amp;gt;RP-A501 is being developed for Danon Disease, a rare genetic disorder characterized by thickening and weakening of the heart muscle, often resulting in heart failure, and for male patients, frequent death during adolescence or early adulthood. Rocket is the first company demonstrating safety and efficacy data in clinical studies for gene therapy targeting the heart. An open-label, global Phase 2 pivotal clinical trial of RP-A501 for the treatment of Danon Disease has commenced. The trial is expected to enroll 12 male patients from the U.S. EU. The trial will assess a co-primary endpoint consisting of LAMP2 protein expression and left ventricular (LV) mass reduction from baseline at 12 months. Natural History studies are observational studies that gather comprehensive data on the course of the disease to gain a better understanding of its progression and impact on patients. Data captured may include information on the physical signs and symptoms patients experience, test results (for example blood tests or imaging), genetic information, and health-related quality of life, over a period of time.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;This information helps describe the disease course and &lt;del class=&quot;diffchange diffchange-inline&quot;&gt; [https://playmobilinfo.com/index.php/FDA_Pauses_PepGen%E2%80%99s_DMD_Drug_Trial_In_The_US improve nitric oxide] &lt;/del&gt;identify important factors (e.g. demographic, genetic, and/or lab test results), that may contribute to better or worse disease outcomes. Travel, &lt;del class=&quot;diffchange diffchange-inline&quot;&gt; [https://test.cuber.co.kr/onyeol/bbs/board.php?bo_table=free&amp;amp;wr_id=112773 Titan Rise Male Enhancement] &lt;/del&gt;accommodation, and food stipend would be provided. Study assessments are provided free of charge. Natural History Studies are particularly important for rare diseases. Given the diversity of symptoms and the small size of the patient population, these studies are often the only opportunity for researchers and physicians to address significant knowledge gaps and obtain a robust understanding of the disease and patient experience. Understanding characteristics of the patient population to define a treatment benefit from a patient’s perspective. Provide patient-centric data for health authorities such as the FDA, and other public health institutions to use in their review processes of investigational treatments. Interested in learning more? To read our Expanded Access statement, click here. RP-A501 is being developed for Danon Disease, a rare genetic disorder characterized by thickening and weakening of the heart muscle, often resulting in heart failure, and for &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;male &lt;/del&gt;patients, frequent death during adolescence or early adulthood.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Rocket is the first company demonstrating safety and efficacy data in clinical studies for gene therapy targeting the heart. An open-label, global Phase 2 pivotal clinical trial of RP-A501 for the treatment of Danon Disease has commenced. The trial is expected to enroll 12 male patients from the U.S. EU. The trial will assess a co-primary endpoint consisting of LAMP2 protein expression and left ventricular (LV) mass reduction from baseline at 12 months. Rocket is sponsoring a multi-center, global, non-interventional natural history study designed to collect longitudinal prospective and retrospective clinical information on male and female patients with Danon Disease. The overarching goal of the study is to characterize the natural history of Danon Disease by collecting de-identified information from patients living with the condition. Initial trial sites for the natural history study in the U.S. EU have been identified and are currently enrolling patients. If you are diagnosed with Danon Disease or a family member and are interested in potentially enrolling in the Danon Disease Natural History Study, please contact us.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Natural History studies are observational studies that gather comprehensive data on the course of the disease to gain a better understanding of its progression and impact on patients. Data captured may include information on the physical signs and symptoms patients experience, test results (for example blood tests or imaging), genetic information, and health-related quality of life, over a period of time. This information helps describe the disease course and identify important factors (e.g. demographic, genetic, and/or [https://&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;pixabay&lt;/del&gt;.com/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;images&lt;/del&gt;/&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;search/lab%20test/ lab test&lt;/del&gt;] &lt;del class=&quot;diffchange diffchange-inline&quot;&gt;results), &lt;/del&gt;that may contribute to better or worse disease outcomes. Travel, accommodation, and food stipend would be provided. Study assessments are provided free of charge. Natural History Studies are particularly important for &lt;del class=&quot;diffchange diffchange-inline&quot;&gt; [http://183.56.232.100:3062/franklinnibbi6/franklin2004/wiki/14+Benefits+of+Strength+Training improve nitric oxide] &lt;/del&gt;rare diseases. Given the diversity of symptoms and the small size of the patient population, these studies are often the only opportunity for researchers and physicians to address significant knowledge gaps and obtain a robust understanding of the disease and patient experience. Understanding characteristics of the patient population to define a treatment benefit from a patient’s perspective. Provide patient-centric data for health authorities such as the FDA, and other public health institutions to use in their review processes of investigational treatments. Interested in learning more? To read our Expanded Access statement, click here. 2025 Rocket Pharmaceuticals. © Rocket Pharmaceuticals, Ltd.&amp;lt;br&amp;gt;&lt;del class=&quot;diffchange diffchange-inline&quot;&gt;[https://www.suecoletta.com/pinterest-for-authors-generate-traffic-and-gain-readers/ suecoletta.com]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;br&amp;gt;RP-A501 is being developed for Danon Disease, a rare genetic disorder characterized by thickening and weakening of the heart muscle, often resulting in heart failure, &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt; [https://gitea.sosaley.in/madeleinedanne/9185alpha-surge-male-supplement/wiki/25-Best-Resistance-Band-Exercises-%26-Q0-Resistance-Band-Workouts-for-every-Muscle-Group Alpha Surge Male strength formula] &lt;/ins&gt;and for male patients, frequent death during adolescence or early adulthood. Rocket is the first company demonstrating safety and &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt; [https://lab.chocomart.kz/gwxleanne50671/2475alpha-surge-male-reviews/issues/11 Alpha Surge Male strength formula] &lt;/ins&gt;efficacy data in clinical studies for gene therapy targeting the heart. An open-label, global Phase 2 pivotal clinical trial of RP-A501 for the treatment of Danon Disease has commenced. The trial is expected to enroll 12 &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;[https://git.ngcr.de/elinorstleon15 alpha surge &lt;/ins&gt;male &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;official site] &lt;/ins&gt;patients from the U.S. EU. The trial will assess a co-primary endpoint consisting of LAMP2 protein expression and left ventricular (LV) mass reduction from baseline at 12 months. Natural History studies are observational studies that gather comprehensive data on the course of the disease to gain a better understanding of its progression and impact on patients. Data captured may include information on the physical signs and symptoms patients experience, test results (for example blood tests or imaging), genetic information, and health-related quality of life, over a period of time.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;This information helps describe the disease course and identify important factors (e.g. demographic, genetic, and/or lab test results), that may contribute to better or worse disease outcomes. Travel, accommodation, and food stipend would be provided. Study assessments are provided free of charge. Natural History Studies are particularly important for rare diseases. Given the diversity of symptoms and the small size of the patient population, these studies are often the only opportunity for researchers and physicians to address significant knowledge gaps and obtain a robust understanding of the disease and patient experience. Understanding characteristics of the patient population to define a treatment benefit from a patient’s perspective. Provide patient-centric data for health authorities such as the FDA, and other public health institutions to use in their review processes of investigational treatments. Interested in learning more? To read our Expanded Access statement, click here. RP-A501 is being developed for Danon Disease, a rare genetic disorder characterized by thickening and &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt; [https://45.76.249.136/index.php?title=User:KlausBehrens Alpha Surge Male strength formula] &lt;/ins&gt;weakening of the heart muscle, often resulting in heart failure, and for &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;[http://www.gitea.zhangc.top:3000/floragalarza8 Alpha Surge Male strength formula] &lt;/ins&gt;patients, frequent death during adolescence or early adulthood.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Rocket is the first company demonstrating safety and efficacy data in clinical studies for gene therapy targeting the heart. An open-label, global Phase 2 pivotal clinical trial of RP-A501 for the treatment of Danon Disease has commenced. The trial is expected to enroll 12 male patients from the U.S. EU. The trial will assess a co-primary endpoint consisting of LAMP2 protein expression and left ventricular (LV) mass reduction from baseline at 12 months. Rocket is sponsoring a multi-center, global, non-interventional natural history study designed to collect longitudinal prospective and retrospective clinical information on &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;[https://gitea.siriusun.com/chandrakaiser alpha surge &lt;/ins&gt;male&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;] &lt;/ins&gt;and female patients with Danon Disease. The overarching goal of the study is to characterize the natural history of Danon Disease by collecting de-identified information from patients living with the condition. Initial trial sites for the natural history study in the U.S. EU have been identified and are currently enrolling patients. If you are diagnosed with Danon Disease or a family member and are interested in potentially enrolling in the Danon Disease Natural History Study, &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt; [http://git.konsulterna.nu:3000/zanetyler78000 alpha surge male official site] [http://git.gkcorp.com.vn:16000/frankiegoodlet alpha surge male supplement] male muscle builder &lt;/ins&gt;please contact us.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Natural History studies are observational studies that gather comprehensive data on the course of the disease to gain a better understanding of its progression and impact on patients. Data captured may include information on the physical signs and symptoms patients experience, test results (for example blood tests or imaging), genetic information, and &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt; [https://wiki.snooze-hotelsoftware.de/index.php?title=Benutzer:Damaris5665 Alpha Surge Male strength formula] &lt;/ins&gt;health-related quality of life, over a period of time. This information helps describe the disease course and identify important factors (e.g. demographic, genetic, and/or &lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;lab test results),&amp;#160; &lt;/ins&gt;[https://&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;wiki.heycolleagues&lt;/ins&gt;.com/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;index.php&lt;/ins&gt;/&lt;ins class=&quot;diffchange diffchange-inline&quot;&gt;User:RafaelKopf75558 Alpha Surge Male strength formula&lt;/ins&gt;] that may contribute to better or worse disease outcomes. Travel, accommodation, and food stipend would be provided. Study assessments are provided free of charge. Natural History Studies are particularly important for rare diseases. Given the diversity of symptoms and the small size of the patient population, these studies are often the only opportunity for researchers and physicians to address significant knowledge gaps and obtain a robust understanding of the disease and patient experience. Understanding characteristics of the patient population to define a treatment benefit from a patient’s perspective. Provide patient-centric data for health authorities such as the FDA, and other public health institutions to use in their review processes of investigational treatments. Interested in learning more? To read our Expanded Access statement, click here. 2025 Rocket Pharmaceuticals. © Rocket Pharmaceuticals, Ltd.&amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>JosetteHandley</name></author>	</entry>

	<entry>
		<id>http://www.vokipedia.de/index.php?title=Natural_History_Studies:_Danon_Disease&amp;diff=93918&amp;oldid=prev</id>
		<title>DerekChavarria: Die Seite wurde neu angelegt: „&lt;br&gt;RP-A501 is being developed for Danon Disease, a rare genetic disorder characterized by thickening and weakening of the heart muscle, often resulting in hea…“</title>
		<link rel="alternate" type="text/html" href="http://www.vokipedia.de/index.php?title=Natural_History_Studies:_Danon_Disease&amp;diff=93918&amp;oldid=prev"/>
				<updated>2025-08-10T00:46:03Z</updated>
		
		<summary type="html">&lt;p&gt;Die Seite wurde neu angelegt: „&amp;lt;br&amp;gt;RP-A501 is being developed for Danon Disease, a rare genetic disorder characterized by thickening and weakening of the heart muscle, often resulting in hea…“&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Neue Seite&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;lt;br&amp;gt;RP-A501 is being developed for Danon Disease, a rare genetic disorder characterized by thickening and weakening of the heart muscle, often resulting in heart failure, and for male patients, frequent death during adolescence or early adulthood. Rocket is the first company demonstrating safety and efficacy data in clinical studies for gene therapy targeting the heart. An open-label, global Phase 2 pivotal clinical trial of RP-A501 for the treatment of Danon Disease has commenced. The trial is expected to enroll 12 male patients from the U.S. EU. The trial will assess a co-primary endpoint consisting of LAMP2 protein expression and left ventricular (LV) mass reduction from baseline at 12 months. Natural History studies are observational studies that gather comprehensive data on the course of the disease to gain a better understanding of its progression and impact on patients. Data captured may include information on the physical signs and symptoms patients experience, test results (for example blood tests or imaging), genetic information, and health-related quality of life, over a period of time.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;This information helps describe the disease course and  [https://playmobilinfo.com/index.php/FDA_Pauses_PepGen%E2%80%99s_DMD_Drug_Trial_In_The_US improve nitric oxide] identify important factors (e.g. demographic, genetic, and/or lab test results), that may contribute to better or worse disease outcomes. Travel,  [https://test.cuber.co.kr/onyeol/bbs/board.php?bo_table=free&amp;amp;wr_id=112773 Titan Rise Male Enhancement] accommodation, and food stipend would be provided. Study assessments are provided free of charge. Natural History Studies are particularly important for rare diseases. Given the diversity of symptoms and the small size of the patient population, these studies are often the only opportunity for researchers and physicians to address significant knowledge gaps and obtain a robust understanding of the disease and patient experience. Understanding characteristics of the patient population to define a treatment benefit from a patient’s perspective. Provide patient-centric data for health authorities such as the FDA, and other public health institutions to use in their review processes of investigational treatments. Interested in learning more? To read our Expanded Access statement, click here. RP-A501 is being developed for Danon Disease, a rare genetic disorder characterized by thickening and weakening of the heart muscle, often resulting in heart failure, and for male patients, frequent death during adolescence or early adulthood.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Rocket is the first company demonstrating safety and efficacy data in clinical studies for gene therapy targeting the heart. An open-label, global Phase 2 pivotal clinical trial of RP-A501 for the treatment of Danon Disease has commenced. The trial is expected to enroll 12 male patients from the U.S. EU. The trial will assess a co-primary endpoint consisting of LAMP2 protein expression and left ventricular (LV) mass reduction from baseline at 12 months. Rocket is sponsoring a multi-center, global, non-interventional natural history study designed to collect longitudinal prospective and retrospective clinical information on male and female patients with Danon Disease. The overarching goal of the study is to characterize the natural history of Danon Disease by collecting de-identified information from patients living with the condition. Initial trial sites for the natural history study in the U.S. EU have been identified and are currently enrolling patients. If you are diagnosed with Danon Disease or a family member and are interested in potentially enrolling in the Danon Disease Natural History Study, please contact us.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Natural History studies are observational studies that gather comprehensive data on the course of the disease to gain a better understanding of its progression and impact on patients. Data captured may include information on the physical signs and symptoms patients experience, test results (for example blood tests or imaging), genetic information, and health-related quality of life, over a period of time. This information helps describe the disease course and identify important factors (e.g. demographic, genetic, and/or [https://pixabay.com/images/search/lab%20test/ lab test] results), that may contribute to better or worse disease outcomes. Travel, accommodation, and food stipend would be provided. Study assessments are provided free of charge. Natural History Studies are particularly important for  [http://183.56.232.100:3062/franklinnibbi6/franklin2004/wiki/14+Benefits+of+Strength+Training improve nitric oxide] rare diseases. Given the diversity of symptoms and the small size of the patient population, these studies are often the only opportunity for researchers and physicians to address significant knowledge gaps and obtain a robust understanding of the disease and patient experience. Understanding characteristics of the patient population to define a treatment benefit from a patient’s perspective. Provide patient-centric data for health authorities such as the FDA, and other public health institutions to use in their review processes of investigational treatments. Interested in learning more? To read our Expanded Access statement, click here. 2025 Rocket Pharmaceuticals. © Rocket Pharmaceuticals, Ltd.&amp;lt;br&amp;gt;[https://www.suecoletta.com/pinterest-for-authors-generate-traffic-and-gain-readers/ suecoletta.com]&lt;/div&gt;</summary>
		<author><name>DerekChavarria</name></author>	</entry>

	</feed>